

Appendix Table F79. Improvement in UI after pharmacological treatments for UI

Active	Dose	Control	Dose	Studies	Patients	Rate in active group	Rate in control group	Relative risk (95% CI)	Absolute risk difference (95%CI)	Number needed to treat (95% CI)	Evidence
Fesoterodine	4-8mg once daily	Tolterodine-ER	4mg daily	4 ^{58,322,372,475}	5,788	56	50	1.08 (1; 1.2)	0.045 (0.014; 0.076)	22 (13; 71)	High
Oxybutynin	10mg daily	Tolterodine	4mg/day	3 ^{226,311,335}	947	50.3	44.7	1.11 (0.94; 1.31)	0.050 (-0.028; 0.128)		Moderate
Propiverine	15mg thrice daily	Oxybutynin	5mg twice daily	1 ³⁴³	294	83.0	79.0	1.05 (0.94; 1.17)	0.039 (-0.050; 0.128)		Insufficient
Solifenacin succinate	5-10mg once daily	Tolterodine	4mg once daily	1 ⁶¹	1,177	74.0	67.0	1.11 (1.03; 1.19)	0.071 (0.019; 0.123)	14 (52; 8)	Insufficient
Flavoxate hydrochloride	1200	Oxybutynin	5mg t.i.d.	1 ³⁴⁸	100	34.0	18.0	1.89 (0.93; 3.83)	0.160 (-0.009; 0.329)		Insufficient
Tropium Chloride	15mg to 30mg thrice daily	Oxybutynin Hydrochloride	2.5mg to 5mg thrice daily	1 ⁴¹¹	1,658	51	64	0.8 (0.5; 1.1)	-0.017 (-0.04; 0.007)		Insufficient